Gnosall Limited investment portfolio

Carbometrics designs and synthesises highly selective synthetic glucose‑binding molecules that enable ultra‑accurate continuous metabolic monitoring, and applies this technology in products such as i‑CAM, a comprehensive metabolic monitor for cardiopulmonary bypass and organ‑perfusion circuits, aimed at healthcare providers and medical‑device manufacturers.

Halo Therapeutics Ltd develops self‑administered antiviral therapies, including an intranasal spray, that target SARS‑CoV‑2 and other coronaviruses for early treatment and prophylaxis. Its products are intended for patients experiencing the first signs of COVID‑19 and for broader coronavirus infection prevention.